AlphAIAlphAI — Financial news for AI agents
247wallst.comOCT 272 min read$TEM

The $1.5 Billion Question Facing Tempus AI Ahead of Nov. 2 Earnings

Tempus AI (TEM) is set to report Q3 earnings around Nov. 2, with revenue expected to grow 22.5% YoY to $409.37M. The company has a pending $1.5B acquisition of Personalis (PSNL) and raised FY2026 revenue guidance to $1.595B-$1.605B. Shares are down 20.36% over the past month.

Original reporting
247wallst.com
Published Oct 27, 2026, 1:28 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 27, 2026, 1:31 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
The $1.5 Billion Question Facing Tempus AI Ahead of Nov. 2 Earnings — source image
Source · 247wallst.com
Decision brief

The 30-second read

$TEMNeutralLow
01

Why it matters

Investors are weighing the earnings beat against the pending acquisition, leading to mixed sentiment and limited trading impetus.

02

Market read

The article provides a recap of already‑released earnings and guidance, offering little new actionable insight.

03

What to watch

Potential dilution from stock‑based compensation and the debt facility backing the acquisition could weigh on valuation.

Relevance 4/10Novelty 2/10Timing: ahead of Nov 2 earnings

Background

Tempus AI reported Q3 results earlier this month and raised full‑year revenue guidance. The $1.5B Personalis deal remains pending, with closing expected late Q4 2026.

Company-level read

Ticker impact

$TEMNeutralMedium confidence
Context

Tempus AI is the article's subject, with its upcoming Q3 earnings and pending $1.5B Personalis acquisition discussed.

Expected impact

likely modest downside or flat as the market prices in earnings uncertainty

Evidence & confidence

No new financial data beyond previously released results; the primary catalyst is the upcoming earnings call, which typically yields limited immediate price movement.

Market effects

Sector

The biotech data‑analytics sector may watch the Personalis acquisition for potential consolidation trends.

Regional

Limited to U.S. biotech investors; no broader regional effect.

Global

Minimal global impact beyond niche biotech investors.

Counterpoint

What could challenge this read

If the Personalis integration proceeds smoothly, the stock could rally post‑earnings despite modest guidance.

Key entities

  • Company
    Tempus AI

    NASDAQ‑listed biotech data‑analytics firm awaiting Q3 earnings.

  • Company
    Personalis

    Target of Tempus AI's $1.5B acquisition.

Read at source← All news

Related articles

OCT 26
$TEMMed

What Happens To Tempus AI Stock If Its Cash Burn Continues?

Tempus AI (TEM) expects positive free cash flow by year-end but had a $273M cash burn over the past year. With $816M in cash, the company's reserves could last about three years at current burn rates. Revenue grew 20% and 36% in diagnostics and data businesses, respectively. Management raised 2026 revenue guidance to $1.595B-$1.605B and issued $460M in convertible notes. The company plans to acquire Personalis, potentially using debt to fund the deal.

finance.yahoo.com2 min
OCT 26
$BMYMed

Pathos AI Announces Strategic Collaborations with Bristol Myers Squibb and Tempus AI to Advance AI-Driven Drug Development Beginning with Alzheimer’s Disease and Other Neurological Conditions

Pathos AI has partnered with Bristol Myers Squibb (BMY) and Tempus (TEM) to advance AI-driven drug development for Alzheimer’s and other neurological conditions. Tempus will create a dataset from hundreds of thousands of patients, which Pathos will license for $55 million over five years. BMY leads Pathos's Series E financing and gains access to Pathos's AI platform, Pathos Foundry, for its R&D portfolio, with exclusive rights in neuroscience for three years.

biospace.com3 min
OCT 24
$BMYMed

Tempus Sets $55 Million Ceiling for Pathos Neurology Data Contract

Tempus AI signed a five-year neurology data deal with Pathos AI, potentially worth $55 million. Tempus will deliver up to 500,000 records, with Pathos paying $100 per record. Bristol Myers Squibb gains nonexclusive Foundry access and three-year exclusive rights for neuroscience development. Tempus also has a $137.5 million oncology deal with BMS, totaling $192.5 million if both deals reach full value.

econotimes.com2 min
OCT 23
$TEMMed

Tempus AI Gains 6% as Bristol Myers Squibb Licenses Oncology Data

Tempus AI shares rose 6% after Bristol Myers Squibb agreed to a multi-year deal to license its oncology data through 2031. Tempus's data and AI platform will support BMS's drug discovery and development. Data licensing is Tempus's most profitable segment, with 36% revenue growth in Q2. The financial terms of the deal were not disclosed.

finance.yahoo.com2 min